Prior Authorization for Orthopaedics: CMS Rule Changes in 2027 (and the 2026 Workflow Moves to Make Now)

On January 1, 2027, Medicare Advantage plans, Medicaid and CHIP programs and their managed care plans, and qualified health plan issuers on the federally facilitated exchanges must operate four new interoperability APIs under CMS-0057-F, including a Prior Authorization API that tells your practice what a payer requires, what documentation is needed, and why a request was denied.

Two of the rule's provisions are already live: since January 1, 2026, those payers have had to decide expedited requests within 72 hours and standard requests within 7 calendar days, give a specific denial reason, and publish their prior authorization approval, denial, and appeal statistics on a public website every year. That last requirement has already produced something orthopaedic practices have never had before: payer-specific denial and overturn rates you can benchmark against. This guide covers what changes, what the new public data shows, and the workflow moves worth making in 2026 rather than waiting.

What CMS-0057-F actually is, and who it binds

The rule's full name is long, but the short version is the CMS Interoperability and Prior Authorization Final Rule, published in the Federal Register on February 8, 2024.

It binds a defined set of "impacted payers": Medicare Advantage organizations, state Medicaid and CHIP fee-for-service programs, Medicaid managed care plans, CHIP managed care entities, and qualified health plan issuers on the federally facilitated exchanges. CMS estimates approximately 15 billion dollars in savings over ten years.

Two exclusions matter for orthopaedic groups. First, the rule does not reach commercial and employer-sponsored plans, which are simply not impacted payers. If your payer mix is heavily commercial, a large share of your prior authorization volume sits outside this rule entirely. Second, none of the prior authorization policies apply to drugs covered by any impacted payer. A separate proposed rule, CMS-0062-P, published April 14, 2026, would extend electronic prior authorization to drugs with an October 1, 2027 compliance date and would close the current exemption that lets exchange QHP issuers skip the decision timeframes. As of this writing it remains a proposal, not a final rule.

There is also a provider-side date. CMS-0057-F created an Electronic Prior Authorization attestation measure in the MIPS Promoting Interoperability category, a yes or no attestation beginning with the CY 2027 performance period.

The provisions already in force since January 2026

Three requirements took effect on January 1, 2026, and orthopaedic practices should be holding payers to them now.

‍Decision timeframes. Impacted payers, other than exchange QHP issuers, must decide expedited requests within 72 hours and standard requests within 7 calendar days. CMS did not require real-time decisions.

‍Specific denial reasons. Payers must provide specific information about a prior authorization denial regardless of how the request was submitted. CMS stated the purpose plainly: to help practices resubmit or appeal. A denial letter that says only "not medically necessary" without naming the criterion or the missing documentation is not what the rule contemplates.

‍Public Metrics reporting. Impacted payers must post annual prior authorization metrics on a public website, including the percentage of requests approved, denied, and approved after appeal, plus the average time from submission to decision. The first reports were due March 31, 2026, covering calendar year 2025.

What the first year of public payer data shows

This is the most useful development in prior authorization transparency in a decade, and most practices have not looked at it yet.

KFF analyzed the newly posted CY2025 disclosures in August 2026. For standard prior authorization requests, it found denial rates of roughly 12 percent in Medicare Advantage, 14 percent in Medicaid managed care, and 18 percent in ACA Marketplace plans. Expedited request denial rates were 10, 12, and 16 percent respectively. Appeal overturn rates were 67 percent for Medicare Advantage, 47 percent for Medicaid managed care, and 43 percent for Marketplace plans.

Forvis Mazars analyzed the same disclosures in August 2026 and reported a median Medicare Advantage denial rate of 7.2 percent, with 12 to 14 percent across Medicaid managed care, CHIP, and Marketplace, and found that only 7.3 percent of denials were appealed while 52.6 percent of appealed denials were overturned. It also reported that by July 2026, 92 percent of payers required to publish CY2025 metrics had done so.

The two analyses do not reconcile cleanly, likely because of different denominators and mean versus median treatment. Use each figure with its source attached rather than blending them. But the direction is unambiguous, and it matches KFF's separate analysis of Medicare Advantage encounter data: in 2024, MA plans made 52.8 million prior authorization determinations and denied 4.1 million of them, 7.7 percent, up from 6.4 percent in 2023. Only 11.5 percent of denials were appealed, and 80.7 percent of appeals were partially or fully overturned.

Read those two numbers together. Eight in ten appealed denials get overturned, and roughly nine in ten denials are never appealed. This is a workflow problem inside your own practice.

The orthopaedic-specific evidence

The general prior authorization burden data is well established. The AMA's 2025 Prior Authorization Physician Survey, fielded in December 2025 across 1,000 practicing physicians, found an average of 40 prior authorizations per physician per week and 13 hours per week spent on them by physicians and staff, with 40 percent of physicians employing staff who work exclusively on prior authorization. Ninety-five percent reported that prior authorization delays access to care.

The orthopaedic evidence is more specific and more damning.

At the AAOS 2025 Annual Meeting, a Rothman Orthopaedic Institute study of 3,922 commercially insured total hip arthroplasty patients from 2020 through 2022 found that 72.4 percent required prior authorization. The initial denial rate was 1.5 percent in the prior authorization cohort versus zero in the cohort that did not require it, any form of denial ran 4.8 percent versus 3.0 percent, addendum submissions were required in 9.4 percent of cases versus zero, and prior authorization added 2.1 days to time to surgery. The authors found no cost savings.

At the AAOS 2026 Annual Meeting, a study of more than 7,000 U.S. adults undergoing elective spine surgery between January 2021 and December 2024 found 460 patients, 6.6 percent, were denied. Of those, 374, or 81.3 percent, ultimately received the surgery anyway, after a mean delay of 15.7 days from denial to approval. The cited denial reasons were lack of six weeks of documented physical therapy at 30 percent, "not medically necessary" at 26.5 percent, and lack of smoking cessation proof at 15 percent. Nearly 31 percent required a peer-to-peer review.

Look at the denial reasons in that spine study. Two of the top three, physical therapy documentation and smoking cessation documentation, are documentation problems your practice controls, not clinical disagreements. That is the single most actionable finding in the orthopaedic prior authorization literature.

Medicare fee-for-service is now in the prior authorization business too

Orthopaedic groups have historically treated traditional Medicare as the one payer without prior authorization friction. That changed on January 1, 2026.

The CMS Innovation Center's Wasteful and Inappropriate Service Reduction model, known as WISeR, runs from January 1, 2026 through December 31, 2031 in six states: New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington. Its service list is heavily musculoskeletal. It includes epidural steroid injections excluding facet joint, percutaneous vertebral augmentation for vertebral compression fracture, cervical fusion, and arthroscopic lavage and debridement for the osteoarthritic knee. CMS delayed implementation for percutaneous image-guided lumbar decompression and deep brain stimulation in an April 2026 notice, and the rest proceeded on schedule.

KFF's February 2026 analysis of the model found that roughly 1.1 million traditional Medicare beneficiaries received at least one WISeR service in 2024, and that more than 900,000 of them, 86 percent, received some form of orthopaedic pain management service. Orthopaedics dominates this model by patient volume.

Two mechanics matter. Prior authorization submission under WISeR is technically optional, but providers who decline face post-service prepayment medical review instead, which typically takes longer. And non-affirmation recommendations must be made by an appropriately licensed human clinician, not a machine. A gold card exemption program for providers with consistently high affirmation rates was planned for 2026, which makes clean submission history directly valuable.

The model has drawn congressional scrutiny, including Congressional Review Act resolutions introduced in May 2026. Confirm current status before making operational commitments around it.

Seven workflow moves to make in 2026

Pull your payers' published metrics and rank them. Every impacted payer in your contract portfolio now publishes approval, denial, and post-appeal approval rates. Build a one-page ranking. Take it into your next contract negotiation and into your peer-to-peer escalation policy. You now have the payer's own numbers.

‍Appeal more. Eight in ten appealed Medicare Advantage prior authorization denials get overturned and roughly nine in ten are never appealed. Set a rule: every clinically supported denial gets appealed, no exceptions, with a named owner and a deadline.

‍Build denial-reason templates from the denial-reason data. The spine study's top reasons were missing physical therapy documentation and missing smoking cessation documentation. Build those requirements into the order set so the documentation exists before the request is submitted, not after the denial arrives.

‍Hold payers to the clock. Seventy-two hours expedited, seven calendar days standard, for impacted payers other than exchange QHPs. Log every breach with the submission timestamp. A logged pattern of timeframe violations is leverage.

‍Demand specific denial reasons. The rule requires them. If you are getting a generic denial, that is a compliance issue, not a fact of life.

‍Ask your payers about their January 2027 API readiness now. The Prior Authorization API will convey documentation requirements and decision responses programmatically. Ask which of your payers will support FHIR-based submission and on what timeline, so you are not integrating on the deadline.

‍If you are in a WISeR state, treat affirmation rate as a managed metric. The gold card path rewards consistently clean submissions.

One caution about the voluntary side of this. AHIP announced an industry pledge in June 2025 covering plans serving roughly 257 million Americans, including standardized FHIR-based submission operational by January 1, 2027 and a target of answering at least 80 percent of electronic prior authorization approvals in real time by 2027. AHIP and BCBSA reported in April 2026 an 11 percent reduction in prior authorizations since June 2025, about 6.5 million fewer requests, and a 15 percent reduction in Medicare Advantage. The AMA reported in May 2026 that only 33 percent of physicians believe the pledge will make a meaningful difference. Plan against the regulation, not the pledge.

Frequently asked questions

Does CMS-0057-F apply to our commercial payers?

No. The rule binds Medicare Advantage organizations, Medicaid and CHIP fee-for-service programs, Medicaid and CHIP managed care plans, and QHP issuers on the federally facilitated exchanges. Commercial and employer-sponsored plans are not impacted payers. If commercial is the majority of your payer mix, this rule improves part of your prior authorization volume and leaves the rest unchanged.

‍What exactly changes on January 1, 2027?

Four APIs go live: an expanded Patient Access API that includes prior authorization information, a Provider Access API that shares claims, encounter, USCDI data, and prior authorization information with in-network providers for attributed patients, a Payer-to-Payer API with a five-year data lookback, and a Prior Authorization API that conveys covered items and services, documentation requirements, and approval or denial responses with specific denial reasons. Payer educational resource requirements also take effect that day.

‍Where do we find a payer's published prior authorization metrics?

On the payer's public website. CMS requires annual posting, with the first reports due March 31, 2026 covering CY2025. Forvis Mazars reported that 92 percent of required payers had published by July 2026. If a payer in your portfolio has not posted, that is worth raising with your provider representative.

‍Should we still be doing peer-to-peer reviews?

Yes, and you should be tracking them. The AAOS 2026 spine study found nearly 31 percent of denied cases required peer-to-peer, and 81.3 percent of denied patients ultimately got their surgery. If the majority of denials reverse, peer-to-peer time is not overhead, it is collections work that happens to be done by a surgeon. Measure the recovered revenue per surgeon hour so you can decide whether to staff around it.

‍Does prior authorization apply to traditional Medicare for orthopaedic services now?

In six states, yes, for a defined list. The WISeR model runs January 2026 through December 2031 in New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington, covering epidural steroid injections excluding facet joint, vertebral augmentation, cervical fusion, and arthroscopic lavage and debridement of the osteoarthritic knee, among other services. Submission is optional but the alternative is prepayment review. Confirm the model's current status, since it has been subject to congressional review.

‍What should we measure to know whether our prior authorization workflow is improving?

Five numbers: prior authorization turnaround time from order to determination, denial rate by payer benchmarked against that payer's published rate, appeal rate as a percentage of denials, appeal overturn rate, and staff hours per authorization. The appeal rate is the one most practices have never measured and the one with the most immediate upside.

See how Maia's AutoCoder supports orthopaedic practices. Book a demo at usemaia.com.